Background. The risk, injury, failure, loss-of-function, end-stage-renal-failure (RIFLE) and acute kidney injury network (AKIN) consensus definitions of acute kidney injury (AKI) were established in part to facilitate comparison of trials. Contrast-induced nephropathy (CIN) has traditionally used a less demanding definition. Objectives. To review use of RIFLE and AKIN as AKI trial outcome variables and contrast these with outcomes for CIN. Methods. We conducted a search of PubMed from 1 January 2005 to 31 December 2008 and 9 trial registries for randomized control trials for preventional or interventional treatment of AKI and CIN. Results. RIFLE or AKIN were outcome variables in 36% (n = 8) of the published (n = 22) and 18% (n = 4) of the current (n = 22) AKI trials. RIFLE was used to triage to intervention in three trials. The urine output definition of RIFLE and AKIN was an outcome in only two trials. In 18% (n = 8) of AKI trials, the CIN definition (increase in serum creatinine of ≥25% and/or ≥44 µmol/l) was the primary outcome. This was also the primary outcome in 56% (n = 13) of published (n = 12) and current (n = 11) CIN trials. Three published CIN trials used RIFLE or AKIN as an outcome (13%). The duration over which outcomes were determined varied from 24 h to 7 days. Conclusions. Considerable heterogeneity remains in outcome variables of AKI and CIN clinical trials. Even when the RIFLE or AKIN criteria were used, they were not applied consistently. There is a need for further consensus on surrogate outcome variables.
Results. RIFLE or AKIN were outcome variables in 36% (n = 8) of the published (n = 22) and 18% (n = 4) of the current (n = 22) AKI trials. RIFLE was used to triage to intervention in three trials. The urine output definition of RIFLE and AKIN was an outcome in only two trials. In 18% (n = 8) of AKI trials, the CIN definition (increase in serum creatinine of ≥25% and/or ≥44 µmol/l) was the primary outcome. This was also the primary outcome in
Introduction
Acute kidney injury (AKI) prevention and intervention trials have generally been unsuccessful [1] . A recent Cochrane review of peri-operative renoprotection trials concluded that there was no evidence that dopamine, diuretics, calcium channel blockers, ACE inhibitors or hydration fluids are beneficial [2] . While meta-analysis provides some support for the use of N-acetylcysteine to prevent contrastinduced nephropathy (CIN) [3, 4] , this remains controversial [5] . Similarly, there is limited evidence that fenoldopam can reduce the risk of AKI, the need for renal replacement therapy and mortality [6] [7] [8] [9] . One motivating force for the acute dialysis quality initiative group (ADQI) and the acute kidney injury network (AKIN) to develop a standardized AKI definition and severity scoring criteria was to facilitate comparison of therapeutic and prevention trials [10] [11] [12] . The RIFLE authors recognized that the underlying disease process, including radiocontrast-induced AKI (CIN) may alter the 'clinical meaning' of each degree of renal dysfunction [10] . Nevertheless, they hoped to apply the criteria across multiple aetiologies [10] . CIN was not explicitly referred to in the published AKIN criteria, although some have taken the AKIN definition to be an alternative to that of The European Society of Urogenital Radiology (ESUR) [13] . The ESUR consensus definition is a serum creatinine increase of 25% or 44 µmol/l (0.5 mg/dl) [14] , both of which have been shown to be associated with increased mortality [13, 15] . This study reviews the impact of RIFLE and AKIN criteria on trial design irrespective of disease aetiology, and contrasts these with outcome variables in CIN prevention trials. Trials were classified as prevention or intervention ( Figure 1 ). For prevention trials, patients at risk were recruited prior to possible insult. For intervention trials, patients were recruited post-insult and after detected functional change or kidney damage. Because CIN has often been considered separately to AKI of other aetiologies, we categorized prevention trials as either AKI or CIN prevention and have analysed these separately. (Table 1 ) differ in three areas: (1) RIFLE stages R, I and F may be defined by a decrease in glomerular filtration rate (GFR), whereas AKIN stages cannot; (2) RIFLE includes two additional renal replacement therapy (RRT) stages, L and E, as outcomes, and (3) AKIN I may be defined by an absolute increase in serum creatinine as well as a relative increase. AKIN recognizes a decrease in function within 48 h (although staging may take longer). The AQDI group recommended that AKI be defined as 'abrupt (1-7 days)' and 'sustained' (lasting at least 24 h) (http://www.ccm.upmc.edu/adqi/ADQI2/ADQI2g1.pdf). Duration did not appear in the seminal RIFLE publication [10] but was included in later publications [17, 18] .
Definitions

RIFLE and AKIN definitions
We defined the AKI trials as RIFLE or AKIN compatible, if RIFLE or AKIN were primary or secondary outcomes, or could be determined by the data collected. AKIN compatibility was very likely (VL) if creatinine was measured at or after 48 h post-procedure, and possible (P) if less than 48 h post-procedure. RIFLE compatibility was VL if creatinine was measured daily over several days, allowing determination of a sustained increase (24 h) and P if it was unclear if creatinine measurements would allow determination of a sustained increase. If creatinine measurements were not continued for 7 days, RIFLE compatibility was marked with the superscript b. If it could not be determined whether sufficient urine output data were available to meet RIFLE/AKIN urine output criteria, the compatibility was marked with the superscript a.
Results
Published trials-AKI
Of 22 published trials, 21 were prevention trials and 1 an intervention trial (Table 3) . Five prevention trials used RIFLE or a >50% increase in creatinine as an outcome [19] [20] [21] 22, 23] . The single intervention trial used RIFLE R as the intervention criterion [24] . Only five trials (23%) reported following patients for the 7 days [7, 21, [25] [26] [27] . Urine output was either not measured, not reported on or not of sufficient duration for classification in 15 (68%) trials. Adapted from [10] and [11] . a The recommendation of the ADQI workgroup (http://www.ccm.upmc.edu/adqi/ADQI2/ADQI2g1.pdf). b A baseline sCr is required. If a measured sCr is unavailable ADQI recommend back-calculating the sCr using the MDRD equation with an estimated GFR of 75 to 100 ml/min. sCr, serum creatinine.
All trials measured creatinine 24-72 h post-procedure and could have used AKIN. Eight trials (36%) measured urine output.
Six AKI prevention trials used a CIN definition within their primary outcome: four used an increase of ≥25% in serum creatinine [19, 21, 28, 29] , one ≥44 µmol/l [22] and one ≥25% or ≥44 µmol/l [30] .
Primary outcomes in 16 studies (73%) were creatinine based. They utilized creatinine clearance [9] , an absolute change or peak or mean creatinine [7, 22, 25, 26, [31] [32] [33] , a relative change in creatinine [19, 21, 23, 28, 29] and a mixture of relative and absolute change [7, 8, 24] . Two of the non-creatinine-based primary outcomes were RRT or death, whilst the others utilized a urinary biomarker of injury. Thirteen trials (59%) used a categorical variable as the primary outcome. Others used mean, peak or mean changes as their primary outcome measure. 
Current registered trials-AKI
Of 22 current trials, 16 were AKI prevention trials and 6 were intervention trials (Tables 2, 4 ). AKIN or RIFLE were primary outcomes in one trial each (T9, T14) and secondary outcomes in two prevention and one intervention trials (T5, T10, T17). In only two trials were the serum creatinine levels measured over 7 days enabling a full RIFLE classification (T16, T17). RIFLE R was the entry criterion in two intervention trials (T19, T22). Only four trials measured urine output (T1, T6, T17, T22). Two trials (T3, T5) used the CIN definition of a serum creatinine increase of ≥25% or ≥44 µmol/l as primary outcome and one trial used an increase of 50% or of 44 µmol/l (T9).
Primary outcomes were creatinine based in 10 of the 22 trials (45%). These were creatinine clearance (T2), a change in eGFR (T8), a categorical variable (T3, T5, T6, T9, T14), a continuous creatinine variable (maximum change, T4, average change relative to baseline, T17) and undefined (T7). For T6, oliguria was an alternative outcome. Other primary outcomes were RRT (T9) or RRT and death (T1, T20), safety (T10, T11, T12), urine output and arterial blood pressure (T22), serum cystatin C and plasma NGAL (T18), plasma NGAL alone (T15), time 'fit-for-discharge' (T16) and undefined AKI (T13, T21).
All intervention trials utilized a different biomarker with which to triage. One used a urinary biomarker of injury assumed to increase prior to change in GFR (T17), and the others markers of a change in function, namely: RIFLE R (T19), RIFLE R, I or F with sepsis or septic shock (T22), oliguria (T18), an increase of 25% or 26.4 µmol/l in serum creatinine (T20) and an undefined measure of AKI (T21).
Published trials-CIN
There were 12 CIN prevention trials (Table 5) . Primary outcomes were an increase in creatinine of ≥25% or ≥44 µmol/l (0.5 mg/dl) [34] [35] [36] , ≥25% only [37, 38] , ≥44 µmol/l only [39] [40] [41] , RRT or death [42] , ≥25% decrease in eGFR, mean peak increase in creatinine [43] and mean creatinine at 24 and 48 h [44] . The duration over which an increase in creatinine was assessed varied from less than 48 h to up to 4 days.
One trial used RIFLE as a secondary outcome [40] . Another had an eGFR decrease of 25% as primary outcome that according to the published definition of RIFLE is the equivalent of a serum creatinine increase of 50%, the eGFR, estimated glomerular filtration rate; AKI, acute kidney injury; sCr, serum creatinine; CrCl, creatinine clearance; RRT, renal replacement therapy. Peak increase in sCr (72 h) Change in sCr (7 days) ≥44 µmol/l sCr increase (3 days) ≥88 µmol/l sCr increase (3 days), sCystatin C (at 24 and 72 h) eGFR, estimated glomerular filtration rate; AKI, acute kidney injury; sCr, serum creatinine; CrCl, creatinine clearance; RRT, renal replacement therapy.
RIFLE R criterion (Table 1 ) [43] . However, this equivalence has recently been disputed [45] . Neither of these trials followed up patients for 7 days. One CIN trial used the AKIN criteria as a secondary outcome [35] . The remaining trials measured creatinine in the 24-to 72-h period post-procedure and potentially could have used AKIN.
Current registered trials-CIN
There were 11 current CIN trials with outcome variables: a ≥25% increase in creatinine (T24, T25, T27, T29, T31), a ≥44 µmol/l increase (T32), peak increase in creatinine (T33), decrease in eGFR (T26) and undefined (T23, T28, T30) (Table 6 ). 
Renal functional status on trial entry
There was a considerable variation in renal status at entry (Tables 3-6 ). Several prevention studies used inclusion/exclusion criteria to limit their cohort to patients with pre-existing impaired renal function (sometimes called chronic kidney disease). There was a large variety in CKD definitions. The most frequent was eGFR ≤ 60 ml/min (seven published and four current trials); three trials used 15-60 ml/min (two published, one current). Some trials used a lower maximum eGFR (≤50 or 40 or 35 ml/min). Others defined a wider eGFR range: 15-90 ml/min. Lower limits of serum creatinine to determine an impaired function group were equally varied ranging from 93/117 µmol/l (female/male) to 150 µmol/l.
Discussion
It is well recognized that serum creatinine is a poor marker of function in an acute setting. Often steady state has not been reached and interventions, such as fluid loading, may change serum creatinine values without necessarily reflecting changing renal function. Creatinine clearance overestimates GFR because of tubular secretion of creatinine. The absolute value of creatinine is itself compromised by the lack of a universal creatinine standard and bias and imprecision can affect outcome [46] . Studies often fail to report the creatinine assay used (30 of 33 of the published studies). These factors compromise the use of creatinine in AKI trials. Furthermore, comparison between trials is made difficult because of the large number of primary and secondary outcome definitions.
Whilst neither RIFLE nor AKIN were routinely used as outcome or triaging variables (22% of all trials), this may reflect the short time since the publication of the consensus definitions. It was 4.5 years from the publication of the RIFLE criteria and 22 months from the publication of the AKIN criteria to the end of the search period. Furthermore, investigators may have specific reasons for choosing other outcome variables. There is ongoing debate over the use of absolute compared with relative changes in plasma creatinine [47, 48] . Few trials measured serum creatinine for the 7 days required to establish AKI according to RIFLE, but most measured for the 48 h required for AKIN. The time required for serum creatinine to rise to a new equilibrium state after a decrease in GFR depends on the half-life of serum creatinine excretion. For a 70-kg man with a GFR of 90 ml/min this is ∼5.5 h and will double if the GFR drops by half. It takes four half-lives to reach 94% of the equilibrium value. Therefore, a typical at risk patient may take 44 h to reach equilibrium, and those with very low GFR, say 15 ml/min, may take 132 h. This suggests that for high-risk patients whose pre-insult GFR is low, serum creatinine measurements are needed for longer than 48 h. Recent creatinine-kinetic modelling suggests that an AKI definition based only on an absolute rise in creatinine over 24-48 h may avoid the need to measure over extended periods [48] . Furthermore, this illustrates how differing inclusion criteria for high-risk patients further compromises comparison between trials. This could be remedied if trials utilized the established definition and staging criteria for CKD [49] .
Urine output was rarely used as an outcome metric, although it is a criterion for both RIFLE and AKIN. This suggests that while clinicians usually monitor urine output carefully, few are comfortable intervening on the basis of urine output alone. Although most studies validating RIFLE and AKIN are creatinine based, modified urine output criteria have been associated with increased mortality [50] [51] [52] [53] . It has been suggested that there is an imbalance between creatinine and urine output criteria [54] .
There was no consistent outcome measure in CIN trials. AKIN or RIFLE were rarely used. Some trials used a relative creatinine change (usually ≥25%) and others an absolute change (>0.5 mg/dl). This absolute change reflects a larger rise than is necessary for entry to stage I of AKIN, while the 25% increase is a lower relative rise to enter the same stage. This anomaly appears to have arisen from the historical use of 0.5 mg/dl as a marker of CIN, perhaps because, over 25 years ago, a smaller value was beyond the precision of the creatinine assay and because of the intra-patient variation in creatinine measurements [55] . CIN trials do not define a standard length of time following contrast to assess the development of AKI. Whilst the CIN trial outcomes were more homogeneous than the AKI outcomes, we know of no pathophysiological or epidemiological reason why they should remain different to the RIFLE and AKIN criteria. Perhaps it is time to bring all aetiologies of AKI together with a common definition and severity staging, as was presumably intended by the RIFLE consensus.
In some trials, changes in urinary NAG and urinary or plasma NGAL have been defined as outcome variables. This is an exciting development. However, caution is required, since the use of biomarkers of kidney damage as outcome variables requires detailed knowledge of the biomarker time course and the pathophysiological changes represented by that biomarker. Few novel biomarkers have been documented this comprehensively. Some tubular injury biomarkers have been assessed as predictors of AKI according to RIFLE or AKIN [56] [57] [58] . However, we recommend these to be assessed against mortality and RRT before being used as outcome variables in clinical trials.
In this survey of non-RRT trials, there were very few intervention trials. This may reflect the difficulty and the lack of success in post-injury trials once a change of renal function has been identified. With the advent of novel injury biomarkers that precede functional change, this paradigm may alter. There is one current trial (T17) that reflects a new paradigm with intervention precipitated by an elevation of a urinary injury biomarker, hypothesized to occur before a change in function, also known as secondary prevention. Figure 1 illustrates how this new paradigm fits into the established prevention and intervention after the detection of a functional change paradigm. This new paradigm is hypothesized to reduce the 'noise' in prevention trials caused by the group of patients without injury, but allows intervention before functional change. This may allow assessment of intervention strategies that prevent or ameliorate functional change. RIFLE and AKIN are regularly used to assess the sensitivity and specificity of novel biomarkers Standard inclusion criteria should be adopted for high risk patients based on the established CKD staging [49] ; a stable eGFR < 60 ml/min should be the minimum degree of renal dysfunction Should urine output be used to define AKI?
Further validation of urine output criteria in multiple centres is needed in order to assess their utility as alternatives to or as equivalents of creatinine change outcome variables Should hard outcomes be reported in small trials?
RRT, death at 7 days and death at 30 days should be included as secondary outcomes even in small trials to facilitate later meta-analysis How should biomarkers of injury be utilized in clinical trials?
(i) As triaging tools following suitable observational pilot studies in equivalent cohorts, (ii) As outcomes if previously validated against RRT or death and with detailed knowledge of time course profiles as predictors of AKI; these studies should support the development of a biomarker panel to allow early intervention [59] . RIFLE and AKIN have been validated as indicators of mortality in epidemiological studies which provides additional justification for their use as trial outcomes [18, 50, 52, 53, [60] [61] [62] [63] [64] [65] . As even small increments in creatinine predict increased mortality [66] [67] [68] , trial outcomes should reflect this. AKIN with a minimum threshold of a 0.3 mg/dl creatinine increase was developed for this purpose. Whether this threshold is too high has been questioned, as even smaller increases are associated with an increase in mortality [67, 69] . Interestingly, even a decrease in creatinine is associated with an increase in mortality [65, 69] . This may be as a result of patients presenting with AKI, whose creatinine subsequently falls to baseline. Continuous variable outcomes, such as the peak, mean or mean difference from baseline creatinine, or the difference from baseline averaged over time from baseline, will automatically reflect small changes in creatinine and may be more discriminatory of differences between placebo and studydrug treated groups [70] . The choice of baseline is crucial and the methodology of estimating baseline by backcalculation from age, gender and race has recently been questioned [70, 71] . Need for RRT reflects high severity loss of function. This is an important outcome metric, but reporting should include details on the criteria used to determine the reason for dialysis. Even in trials not powered to assess mortality or need for dialysis, these data should be reported in order to facilitate later meta-analysis.
Conclusion
AKI trials remain difficult to compare because of inconsistencies in the AKI criteria currently being used and because of post hoc modifications of the criteria not based on rigorous consensus processes. Neither RIFLE nor AKIN are routinely used as outcome variables, even in post hoc analysis. Differences in CIN trial outcomes and in renal function status at trial entry compound these difficulties. Areas where further consensus is needed are summarized in Table 7 . The clear-cut association of mortality with relatively small, abrupt changes in serum creatinine needs to be considered in future consensus criteria. In the interim, we recommend that all trials report inclusion criterion and outcomes in RIFLE and AKIN compatible format, even if these are not the primary outcome.
